Rehabilitation in Intensive Care Unit

NCT04713540 | Unknown

• 1 other identifier: intensive care unit
• Study Type: observational
• Target: 58
• Locations: 1 country
• Sites: 1

Brief Summary

It was aimed to evaluate the respiratory functions of patients who were hospitalized in intensive care due to Covid-19 and given respiratory rehabilitation, in-bed positioning, and early mobilization, and the time of leaving the intensive care unit.

Conditions

Covid19

Outcome Measures

Primary Outcomes (3)

• Glaskow coma scale

  The Scale was described in 1974 by Graham Teasdale and Bryan Jennett (Assessment of coma and impaired consciousness. A practical scale. Lancet 1974; 2:81-4.) as a way to communicate about the level of consciousness of patients with an acute brain injury.

  Change from Baseline Glaskow coma scale at 6 months

• APACHE II

  APACHE II ("Acute Physiology And Chronic Health Evaluation II") is a severity-of-disease classification system (Knaus et al., 1985),\[1\] one of several ICU scoring systems. It is applied within 24 hours of admission of a patient to an intensive care unit (ICU): an integer score from 0 to 71 is computed based on several measurements; higher scores correspond to more severe disease and a higher risk of death.

  Change from Baseline mMRC Dyspnea Scale at 6 months

• mMRC Dyspnea Scale

  The mMRC Dyspnea Scale quantifies disability attributable to breathlessness, and is useful for characterizing baseline dyspnea in patients with respiratory diseases. Describes baseline dyspnea, but does not accurately quantify response to treatment of chronic obstructive pulmonary disease (COPD).

  Change from Baseline mMRC Dyspnea Scale at 6 months

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients with covid-19

You may qualify if:

• Being over the age of 18
• Those who have been hospitalized since 11.01.2020
• Those who have been consulted in the physical therapy clinic since 11.01.2020

You may not qualify if:

• Fever ˃38.0 °
• Initial consultation time ˂7 days
• Those with ≤3 days from the onset of the disease to shortness of breath
• Chest radiographic scans showing 50% progression within 24 to 48 hours
• With Spo2 level ≤95%
• Resting blood pressure ˂90 / 60 (1mmHg = 0.133kPa) or ˃140 / 90mmHg.
• ˃100 heart rate per minute
• Those with moderate and / or severe heart disease

Sponsors & Collaborators

• Bakirkoy Dr. Sadi Konuk Research and Training Hospital: lead

Study Sites (1)

Bakirkor Dr. Sadi Konuk Research and Training hospital

Istanbul, 34147, Turkey (Türkiye)

RECRUITING

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Study Officials

• Sibel Çağlar

  Bakırkoy Dr. Sadi Konuk Training and Research Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Sibel Çağlar

CONTACT

+905333365651; sibelcaglarokur@gmail.com

Tuba Altun

CONTACT

+905525780411; tubasaltun@gmail.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER GOV
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: January 14, 2021
• First Posted: January 19, 2021
• Study Start: January 1, 2021
• Primary Completion: April 1, 2021
• Study Completion: May 1, 2021
• Last Updated: January 20, 2021

Record last verified: 2021-01

Locations

TU (1)